China Capital Investment Group is the famous VC, which was founded in 1995. The leading representative office of defined VC is situated in the Shanghai. The fund was located in Asia if to be more exact in China.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the China Capital Investment Group, startups are often financed by YF Capital (Yunfeng Capital), ZhenFund, Zhejiang Provincial Financial Holdings. The meaningful sponsors for the fund in investment in the same round are Zhejiang Paradise, Gaorong Capital, Yunqi Partners. In the next rounds fund is usually obtained by Zero2IPO Ventures, Zhejiang Paradise, Whales Capital.
Among the most successful fund investment fields, there are Therapeutics, Marketing. The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Yunxi Technology, Zhangshang Tangyi, Dingdang Kuaiyao. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.
The fund is constantly included in 2-6 investment rounds annually. Speaking about the real fund results, this VC is 36 percentage points more often commits exit comparing to other organizations. The average startup value when the investment from China Capital Investment Group is 500 millions - 1 billion dollars. The common things for fund are deals in the range of 50 - 100 millions dollars. The important activity for fund was in 2019.
Besides them, we counted 1 critical employee of this fund in our database.
Related Funds
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Aerospace Yuxing | $77M | 06 May 2024 | Haidian, Beijing, China | ||
Kenweiting | $1M | 15 Nov 2023 | Hunan, Hunan, China | ||
Binhui Biotech | $92M | 10 Feb 2021 | Wuhan, Hubei, China | ||
Vision Medicals | $30M | 04 Feb 2021 | Yuexiu District, Guangdong Province, China | ||
VitaVitro Biotech | $15M | 07 Sep 2020 | Shenzhen, Guangdong, China | ||
31 Oct 2019 | China, Beijing | ||||
Yunxi Technology | $54M | 25 Oct 2019 | China, Zhejiang | ||
Waterdrop | $154M | 12 Jun 2019 | Dongcheng District, Beijing, China | ||
INXX | $17M | 01 Apr 2019 | Hong Kong Island, Hong Kong |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Aerospace Yuxing | $77M | 06 May 2024 | Haidian, Beijing, China | ||
Kenweiting | $1M | 15 Nov 2023 | Hunan, Hunan, China | ||
Binhui Biotech | $92M | 10 Feb 2021 | Wuhan, Hubei, China | ||
Vision Medicals | $30M | 04 Feb 2021 | Yuexiu District, Guangdong Province, China | ||
VitaVitro Biotech | $15M | 07 Sep 2020 | Shenzhen, Guangdong, China | ||
31 Oct 2019 | China, Beijing | ||||
Yunxi Technology | $54M | 25 Oct 2019 | China, Zhejiang | ||
Waterdrop | $154M | 12 Jun 2019 | Dongcheng District, Beijing, China | ||
INXX | $17M | 01 Apr 2019 | Hong Kong Island, Hong Kong |